Evidence map›Paper›PMID 42454046›Full record

ReviewFrontiers in immunology2026

NAT10: a potential factor to reverse tumor chemotherapy resistance and radioresistance (Review).

Shijiao Li, Yuan Fang, Yixu Fan, Hao Niu, Xia Sun, Zhenyu Xue, Rui Ling, Ye Hua, Xiang Tang

Erratum issuedAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Shijiao LiDepartment of Head and Neck & General Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Yuan FangDepartment of Abdominal Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Yixu FanDepartment of Thoracic Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Hao NiuDepartment of Head and Neck & General Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Xia SunDepartment of Cardiology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Zhenyu XueDepartment of Head and Neck & General Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Rui LingDepartment of Thoracic Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Ye HuaDepartment of Head and Neck & General Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Xiang TangDepartment of Abdominal Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

NAT10 (N-acetyltransferase 10) is a nucleolar acetyltransferase with catalytic acetylation function, which is currently the only known acetyltransferase that catalyzes the N4-acetylcytidine (ac4C) modification in RNA. As the "writer" protein for ac4C, NAT10 plays a critical role in various biological and pathological processes. In this article, we first introduce the structural and functional characteristics of NAT10, followed by a comprehensive synthesis of its multifaceted molecular mechanisms orchestrating tumor radiotherapy and chemotherapy resistance. Specifically, we emphasize its roles in hyperactivating DNA damage repair (DDR), driving metabolic reprogramming (including evasion of ferroptosis), and facilitating tumor immune evasion via PD-L1 regulation and T-cell suppression. Furthermore, we critically evaluate the translational implications of NAT10-targeted interventions, highlighting the therapeutic promise of specific inhibitors like Remodelin and the repurposed FDA-approved drug Fludarabine. We believe that understanding the functions and mechanisms of NAT10 in tumors will significantly improve the diagnosis, treatment, and prognosis of cancer.

Indexed as

AcetyltransferasesDrug Resistance, NeoplasmNeoplasmsRadiation ToleranceAcetylationAnimalsDNA RepairHumansN-Terminal AcetyltransferasesAcetyltransferasesNAT10 protein, humanN-Terminal Acetyltransferasescancer drug resistancechemoresistanceDNA damage repairNAT10radioresistanceRNA acetylation

Identifiers

PMID42454046
PMCPMC13365181

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.